Prolgolimab clinical trials
Also written BCD-100.
How each study uses prolgolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prolgolimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Biocad (7) · Blokhin's Russian Cancer Research Center (1) · St. Petersburg State Pavlov Medical University (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses prolgolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin LymphomaRecruitingPhase 2St. Petersburg State Pavlov Medical UniversityNCT05757466Written as Prolgolimab
- Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal CancerCompletedPhase 2Blokhin's Russian Cancer Research CenterNCT06428487Written as Prolgolimab
- Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownPhase 3BiocadNCT05783882Written as Prolgolimab
- Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)Status unknownPhase 2/3BiocadNCT03288870Written as BCD-100
- International Trial of the Efficacy and Safety of BCD-100 in Patients With MelanomaStatus unknownPhase 2BiocadNCT03269565Written as BCD-100
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)Status unknownPhase 3BiocadNCT03912415Written as BCD-100
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLCStatus unknownPhase 3BiocadNCT03912389Written as BCD-100
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)Status unknownPhase 2BiocadNCT03912402Written as BCD-100
- A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid TumorsStatus unknownPhase 1BiocadNCT03050047Written as BCD-100
Given beside what is tested · 2 — prolgolimab is usual care or a partner of the new treatment
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingPhase 3BiocadNCT05732805Written as BCD-100
- Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownPhase 2BiocadNCT03913923Written as BCD-100
Codes
What other systems call prolgolimab · ClinicalTrials.gg INT018285
- UNII (FDA) W05CP6IT8RPROLGOLIMABOne source FDA
- NCI Thesaurus C148155ProlgolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W05CP6IT8R | PROLGOLIMAB | One source FDA |
| NCI Thesaurus | C148155 | Prolgolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.